Literature DB >> 27875942

A combined study of MEG and pico-Tesla TMS on children with autism disorder.

Photios Anninos1, Athanasios Chatzimichael2, Adam Adamopoulos1, Athanasia Kotini1, Nicolaos Tsagas3.   

Abstract

Magnetoencephalographic (MEG) recordings from the brain of 10 children with autism (6 boys and 4 girls, with ages range from 5-12 years, mean[Formula: see text][Formula: see text][Formula: see text]SD: 8.3[Formula: see text][Formula: see text][Formula: see text]2.1) were obtained using a whole-head 122-channel MEG system in a magnetically shielded room of low magnetic noise. A double-blind experimental design was used in order to look for possible effect of external pico-Tesla Transcranial Magnetic Stimulation (pT-TMS). The pT-TMS was applied on the brain of the autistic children with proper field characteristics (magnetic field amplitude: 1-7.5[Formula: see text]pT, frequency: the alpha - rhythm of the patient 8-13[Formula: see text]Hz). After unblinding it was found a significant effect of an increase of frequencies in the range of 2-7[Formula: see text]Hz across the subjects followed by an improvement and normalization of their MEG recordings. The statistical analysis of our results showed a statistical significance at 6 out of 10 patients (60%). It is also observed an increase of alpha activity in autistic children at the end of one month after pT-TMS treatment at home. In conclusion, the application of pT-TMS has the prospective to be a noninvasive, safe and important modality in the management of autism children.

Entities:  

Keywords:  MEG; autism children; double blind; pT-TMS

Mesh:

Year:  2016        PMID: 27875942     DOI: 10.1142/S0219635216500278

Source DB:  PubMed          Journal:  J Integr Neurosci        ISSN: 0219-6352            Impact factor:   2.117


  8 in total

1.  Overexpression of microRNA-936 suppresses non-small cell lung cancer cell proliferation and invasion via targeting E2F2.

Authors:  Xiao Zhou; Hui Tao
Journal:  Exp Ther Med       Date:  2018-07-20       Impact factor: 2.447

Review 2.  A Brief Introduction to Magnetoencephalography (MEG) and Its Clinical Applications.

Authors:  Alfred Lenin Fred; Subbiahpillai Neelakantapillai Kumar; Ajay Kumar Haridhas; Sayantan Ghosh; Harishita Purushothaman Bhuvana; Wei Khang Jeremy Sim; Vijayaragavan Vimalan; Fredin Arun Sedly Givo; Veikko Jousmäki; Parasuraman Padmanabhan; Balázs Gulyás
Journal:  Brain Sci       Date:  2022-06-15

3.  The Effect of pT-TMS on Beta Rhythm in Children with Autism Disorder. A MEG Study.

Authors:  Photios Anninos; Athanasios Chatzimichael; Nicolia Anninou; Athanasia Kotini; Adam Adamopoulos; Triandafillos Gemousakakis; Nicolaos Tsagas
Journal:  Maedica (Buchar)       Date:  2019-12

Review 4.  Transcranial Magnetic Stimulation in Autism Spectrum Disorders: Neuropathological Underpinnings and Clinical Correlations.

Authors:  Manuel F Casanova; Estate M Sokhadze; Emily L Casanova; Xiaoli Li
Journal:  Semin Pediatr Neurol       Date:  2020-06-24       Impact factor: 1.636

5.  Long Noncoding RNA FEZF1-AS1 Promotes Osteosarcoma Progression by Regulating the miR-4443/NUPR1 Axis.

Authors:  Chengwei Zhou; Jianxiang Xu; Jinti Lin; Renjin Lin; Kai Chen; Jianzhong Kong; Xiaolong Shui
Journal:  Oncol Res       Date:  2018-02-22       Impact factor: 5.574

6.  Long Noncoding RNA FGFR3-AS1 Promotes Hepatocellular Carcinoma Carcinogenesis via Modulating the PI3K/AKT Pathway.

Authors:  Juhua Zhuang; Saifei He; Guoyu Wang; Guangdong Wang; Jing Ni; Suiliang Zhang; Ying Ye; Wei Xia
Journal:  Oncol Res       Date:  2018-02-20       Impact factor: 5.574

7.  Repetitive Transcranial Magnetic Stimulation for Treatment of Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.

Authors:  J Bernardo Barahona-Corrêa; Ana Velosa; Ana Chainho; Ricardo Lopes; Albino J Oliveira-Maia
Journal:  Front Integr Neurosci       Date:  2018-07-09

8.  MicroRNA‑3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.

Authors:  Taotao Shou; Huyin Yang; Jia Lv; Dai Liu; Xiaoyang Sun
Journal:  Mol Med Rep       Date:  2018-11-27       Impact factor: 2.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.